148 related articles for article (PubMed ID: 22775439)
21. Discrepancy in BRAF status among patients with metastatic malignant melanoma: A meta-analysis.
Valachis A; Ullenhag GJ
Eur J Cancer; 2017 Aug; 81():106-115. PubMed ID: 28623774
[TBL] [Abstract][Full Text] [Related]
22. Benign nodal nevi frequently harbor the activating V600E BRAF mutation.
Taube JM; Begum S; Shi C; Eshleman JR; Westra WH
Am J Surg Pathol; 2009 Apr; 33(4):568-71. PubMed ID: 19033861
[TBL] [Abstract][Full Text] [Related]
23. Assessment of BRAF and KIT mutations in Japanese melanoma patients.
Ashida A; Uhara H; Kiniwa Y; Oguchi M; Murata H; Goto Y; Uchiyama A; Ogawa E; Hayashi K; Koga H; Okuyama R
J Dermatol Sci; 2012 Jun; 66(3):240-2. PubMed ID: 22534474
[No Abstract] [Full Text] [Related]
24. Molecular diagnostics of melanoma fine-needle aspirates: a cytology-histology correlation study.
Bernacki KD; Betz BL; Weigelin HC; Lao CD; Redman BG; Knoepp SM; Roh MH
Am J Clin Pathol; 2012 Nov; 138(5):670-7. PubMed ID: 23086767
[TBL] [Abstract][Full Text] [Related]
25. Comparison of targeted next generation sequencing (NGS) versus isolated BRAF V600E analysis in patients with metastatic melanoma.
Zhu ML; Zhou L; Sadri N
Virchows Arch; 2018 Sep; 473(3):371-377. PubMed ID: 29926184
[TBL] [Abstract][Full Text] [Related]
26. Urgent treatment of patients with metastatic melanoma using Braf inhibitors in the absence of Braf mutation status.
Nathan P; Sharma A; Lorigan P
Ann Oncol; 2013 Jun; 24(6):1712-3. PubMed ID: 23613475
[No Abstract] [Full Text] [Related]
27. B-RAF mutations in tumors from melanoma-breast cancer families.
Gast A; Försti A; Söderberg M; Hemminki K; Kumar R
Int J Cancer; 2005 Jan; 113(2):336-7. PubMed ID: 15386414
[No Abstract] [Full Text] [Related]
28. Primary dermal melanoma: A case report and molecular characterization.
Hida Y; Kubo Y; Miyajima O; Arase S
J Dermatol; 2009 Jun; 36(6):346-52. PubMed ID: 19500183
[TBL] [Abstract][Full Text] [Related]
29. Marked genetic differences between BRAF and NRAS mutated primary melanomas as revealed by array comparative genomic hybridization.
Lázár V; Ecsedi S; Vízkeleti L; Rákosy Z; Boross G; Szappanos B; Bégány A; Emri G; Adány R; Balázs M
Melanoma Res; 2012 Jun; 22(3):202-14. PubMed ID: 22456166
[TBL] [Abstract][Full Text] [Related]
30. Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma.
Long GV; Wilmott JS; Capper D; Preusser M; Zhang YE; Thompson JF; Kefford RF; von Deimling A; Scolyer RA
Am J Surg Pathol; 2013 Jan; 37(1):61-5. PubMed ID: 23026937
[TBL] [Abstract][Full Text] [Related]
31. Re: Determinants of BRAF mutations in primary melanomas.
Purdue MP
J Natl Cancer Inst; 2005 Mar; 97(5):401-2; author reply 402. PubMed ID: 15741578
[No Abstract] [Full Text] [Related]
32. BRAF, NRAS and HRAS mutations in spitzoid tumours and their possible pathogenetic significance.
Da Forno PD; Pringle JH; Fletcher A; Bamford M; Su L; Potter L; Saldanha G
Br J Dermatol; 2009 Aug; 161(2):364-72. PubMed ID: 19438459
[TBL] [Abstract][Full Text] [Related]
33. Method of mutation analysis may contribute to discrepancies in reports of (V599E)BRAF mutation frequencies in melanocytic neoplasms.
Miller CJ; Cheung M; Sharma A; Clarke L; Helm K; Mauger D; Robertson GP
J Invest Dermatol; 2004 Nov; 123(5):990-2. PubMed ID: 15482489
[No Abstract] [Full Text] [Related]
34. Targeting mutant BRAF and KIT in metastatic melanoma: ASCO 2009 meeting report.
Sondak VK; Smalley K
Pigment Cell Melanoma Res; 2009 Aug; 22(4):386-7. PubMed ID: 19624312
[No Abstract] [Full Text] [Related]
35. Immunohistochemical analysis of BRAF(V600E) expression of primary and metastatic melanoma and comparison with mutation status and melanocyte differentiation antigens of metastatic lesions.
Busam KJ; Hedvat C; Pulitzer M; von Deimling A; Jungbluth AA
Am J Surg Pathol; 2013 Mar; 37(3):413-20. PubMed ID: 23211290
[TBL] [Abstract][Full Text] [Related]
36. Malignant melanoma in a woman with LEOPARD syndrome: identification of a germline PTPN11 mutation and a somatic BRAF mutation.
Seishima M; Mizutani Y; Shibuya Y; Arakawa C; Yoshida R; Ogata T
Br J Dermatol; 2007 Dec; 157(6):1297-9. PubMed ID: 17927788
[No Abstract] [Full Text] [Related]
37. Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis.
Willmore-Payne C; Holden JA; Tripp S; Layfield LJ
Hum Pathol; 2005 May; 36(5):486-93. PubMed ID: 15948115
[TBL] [Abstract][Full Text] [Related]
38. Testing and clinical implications for non-V600 BRAF mutations in metastatic NRAS
Richtig G; Richtig E; Kashofer K; Koch L; Winter G; Hoefler G; Pichler M; Ehall B; Grübler MR; Heinemann A; Aigelsreiter A
Br J Dermatol; 2017 Sep; 177(3):860-861. PubMed ID: 27925152
[No Abstract] [Full Text] [Related]
39. Selumetinib increases the efficacy of first-line dacarbazine.
Cancer Discov; 2013 Jul; 3(7):OF16. PubMed ID: 23847359
[TBL] [Abstract][Full Text] [Related]
40. Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis.
Lee JH; Choi JW; Kim YS
Br J Dermatol; 2011 Apr; 164(4):776-84. PubMed ID: 21166657
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
